SCHEMBL3490607

SCHEMBL3490607

Cc1ccc(S(=O)(=O)NC(=N)NCCCCCCOCc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.46
GAA P10253 3/20 0.45
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
ALDH1A1 P00352 4/20 0.44
LMNA P02545 2/20 0.44
ALB P02768 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
AR P10275 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
CA12 O43570 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
ATM Q13315 1/20 0.42
CA9 Q16790 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489489 0.91 GAA (0.48) GAACA1CA2ALDH1A1LMNA
SCHEMBL3488972 0.79 ALDH1A1 (0.53) CA1CA2ALDH1A1LMNAALB
SCHEMBL18221849 0.78 ALDH1A1 (0.60) RAB9AGAACA2ALDH1A1LMNA
SCHEMBL27538377 0.77 ALDH1A1 (0.54) RAB9AALDH1A1LMNAALBCYP2C9
SCHEMBL1395612 0.75 ALDH1A1 (0.72) RAB9AGAAALDH1A1LMNANPSR1
SCHEMBL11058142 0.75 ALDH1A1 (0.55) CA1CA2ALDH1A1LMNAALB
SCHEMBL7756413 0.74 MMP2 (0.53) RAB9AGAACA1CA2ALDH1A1
SCHEMBL13435328 0.74 GAA (0.50) RAB9AGAAALDH1A1LMNAALB
SCHEMBL29025356 0.74 EPHX2 (0.57) RAB9ALMNATSHRTDP1L3MBTL1
SCHEMBL25206305 0.74 ALDH1A1 (0.48) GAACA1CA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150359899-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS BOTTI PAOLO (CH) 2015-12-17 US disclosed
US-9211340-B2 Means and methods of enhancing delivery to biological systems CAPSUGEL BELGIUM (BE) 2015-12-15 US disclosed
EP-2561891-A2 Means and methods of enhancing delivery to biological systems Botti, Paolo (CH) 2013-02-27 EP disclosed
US-20100062050-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS CAPSUGEL BELGIUM (BE) 2010-03-11 US disclosed
EP-2068936-A2 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS Botti, Paolo (CH) 2009-06-17 EP disclosed
WO-2008037463-A2 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS BOTTI PAOLO (CH) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100062050-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS SGTA, GHRHR, IL36G RAB9A 3683/4885GAA 673/4885CA1 1547/4885
US-20150359899-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS PTMS, HGFAC, SLC43A1 RAB9A 3508/4885GAA 474/4885CA1 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.